MedPath

OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.otsuka-us.com

A Trial of Centanafadine Efficacy and Safety in Adults With Attention-deficit/Hyperactivity Disorder and Comorbid Anxiety

Phase 3
Recruiting
Conditions
ADHD
Anxiety
Generalized Anxiety
Social Anxiety Disorder
Interventions
Other: Placebo
First Posted Date
2025-05-15
Last Posted Date
2025-05-31
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
308
Registration Number
NCT06973577
Locations
🇺🇸

Clinical Research Site #017 - Harmonex Neuroscience Research, Dothan, Alabama, United States

🇺🇸

Clinical Research Site #011 - NRC Research Institute, Orange, California, United States

🇺🇸

Clinical Research Site #005 - Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States

and more 5 locations

A Study to Evaluate the Safety and Efficacy of JNT-517 in Participants With Phenylketonuria (PKU)

Phase 3
Not yet recruiting
Conditions
Phenylketonuria
Interventions
Drug: JNT-517 Tablet
First Posted Date
2025-05-14
Last Posted Date
2025-06-03
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
120
Registration Number
NCT06971731

A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's

Phase 2
Not yet recruiting
Conditions
Sjogren Disease
Interventions
First Posted Date
2025-04-15
Last Posted Date
2025-04-15
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
80
Registration Number
NCT06928142
Locations
🇺🇸

Medvin Clinical Research - Riverside, Riverside, California, United States

🇺🇸

Medvin Clinical Research - Tujunga, Tujunga, California, United States

🇺🇸

Bay Area Arthritis and Osteoporosis, Brandon, Florida, United States

and more 15 locations

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

Phase 3
Recruiting
Conditions
Schizophrenia
Interventions
Other: Placebo
First Posted Date
2025-03-25
Last Posted Date
2025-05-18
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
522
Registration Number
NCT06894212
Locations
🇺🇸

Pillar Clinical Research LLC - Bentonville Site # 145, Bentonville, Arkansas, United States

🇺🇸

Pillar Clinical Research (Little Rock AR) Site #153, Little Rock, Arkansas, United States

🇺🇸

Woodland International Research Group Site #141, Little Rock, Arkansas, United States

and more 31 locations

A Proof-of-concept Trial for OPC 131461 in Patients Hospitalized for Worsening Heart Failure

Phase 2
Not yet recruiting
Conditions
Heart Failure
Interventions
Drug: Placebo
First Posted Date
2025-03-25
Last Posted Date
2025-03-27
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
264
Registration Number
NCT06795399

A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)

Phase 1
Recruiting
Conditions
Systemic Lupus Erythematosus (SLE)
Alopecia Areata (AA)
Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)
Interventions
First Posted Date
2025-01-29
Last Posted Date
2025-04-11
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
30
Registration Number
NCT06799520
Locations
🇲🇩

Visterra Investigational Site, Chisinau, Moldova, Republic of

Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue

Phase 2
Recruiting
Conditions
IgA Nephropathy
Interventions
First Posted Date
2024-12-18
Last Posted Date
2025-04-06
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
25
Registration Number
NCT06740526
Locations
🇺🇸

Clinical Research Site 330, Denver, Colorado, United States

🇺🇸

Clinical Research Site 369, Boston, Massachusetts, United States

🇺🇸

Clinical Research Site 374, Dakota Dunes, South Dakota, United States

and more 2 locations

A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria

Phase 2
Not yet recruiting
Conditions
Phenylketonuria (PKU)
Interventions
Drug: JNT-517 Tablet
Other: Placebo
First Posted Date
2024-10-15
Last Posted Date
2025-06-03
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
10
Registration Number
NCT06637514

A Study to Evaluate the Long-Term Safety and Efficacy of JNT-517 in Participants With Phenylketonuria

Phase 3
Not yet recruiting
Conditions
Phenylketonuria (PKU)
Interventions
Drug: JNT-517 Tablet
First Posted Date
2024-10-04
Last Posted Date
2025-06-03
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
45
Registration Number
NCT06628128

A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion

Not Applicable
Completed
Conditions
Mental Disorder
Schizophrenia
Major Depressive Disorder
Bipolar I Disorder
Interventions
Drug: Placebo IEM tablet
Device: D-Tect Patch
First Posted Date
2024-04-17
Last Posted Date
2024-07-31
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
54
Registration Number
NCT06372210
Locations
🇺🇸

Research site, Garden Grove, California, United States

© Copyright 2025. All Rights Reserved by MedPath